Chemestmed is an epitranscriptomics company
developing a technological platform for the discovery of novel drugs
based on mRNA regulation in cells.

The world is in the midst of a therapeutic revolution and
Estonia-based company Chemestmed operates at the forefront of it

Traditional drug development targets directly the disease-causing ill-behaving proteins. During the past several years, another direction has rapidly emerged. It is based on the regulation of the cellular processes at the RNA level and is expected to change the standard of care for many diseases.
The resulting treatments are expected to be more cost effective, relatively simple to manufacture, and can target previously undruggable pathways. The respective research, called epitranscriptomics, studies chemical modifications to RNA, and the proteins & enzymes that write, erase, and read these modifications.

The most abundant RNA modification of mammalian mRNAs that also plays a vital role in many diseases is N6-methyladenosine (m6A). We have developed active substances for almost all enzymes involved in the regulation of RNA m6A, and proven them in biological experiments. Our biggest achievement is the discovery of the world's first m6A methylation activators (Selberg S et al. Cell Reports, 2019; 26:3762). www.cell.com/cell-reports/pdf/S2211-1247(19)30286-4.pdf

We are on the mission to develop disruptive therapeutics for a variety of neurodegenerative and neuropsychiatric diseases, cancer and viral infections.

Our programs target diseases spanning several therapeutic areas where there is a high unmet need, there are no approved therapies, or there are significant shortcomings with existing treatment paradigms.

Our active preclinical pipeline consists of the lead candidate CHMA1004 for the treatment of depression, anxiety, Parkinson’s and post-traumatic stress disorder (PTSD) and other compounds for the treatment of cancer and neurodegenerative disorders.

We are a world-leading team of experts in molecular design, neuropsychiatric disorders, virology, cardiovascular diseases and pharmacology

Executive Team

Mihkel Märtson
CEO
Neinar Seli
PhD, founder

Advisory Board

Prof. Andres Merits
Dr. Esko Kankuri
Dr. Anna Kula-Păcurar
Dr. Sigrid Selberg
Silver Saarva
>

Get In Touch

To develop our technology and pipeline, we are looking for partners to establish research collaborations, co-development and license agreements.